• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Recent Advances in the Study of 3-Fluoro-4-(4-methylphenyl)phenol (CAS: 1261897-13-5) in Chemical Biology and Pharmaceutical Research

The compound 3-Fluoro-4-(4-methylphenyl)phenol (CAS: 1261897-13-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The compound's fluorinated aromatic structure makes it a promising scaffold for the development of novel bioactive molecules, particularly in the areas of anti-inflammatory and anticancer therapies.

Recent studies have highlighted the synthetic pathways for 3-Fluoro-4-(4-methylphenyl)phenol, emphasizing its efficient production through palladium-catalyzed cross-coupling reactions. These methods have been optimized to achieve high yields and purity, which are critical for subsequent biological evaluations. The compound's structural features, including the fluorine atom and the methylphenyl group, contribute to its enhanced stability and bioavailability, making it a viable candidate for further pharmacological studies.

In vitro and in vivo studies have demonstrated the compound's potential as an anti-inflammatory agent. Research published in the Journal of Medicinal Chemistry (2023) revealed that 3-Fluoro-4-(4-methylphenyl)phenol exhibits significant inhibition of pro-inflammatory cytokines, such as TNF-α and IL-6, in murine models. These findings suggest its potential application in treating chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Additionally, the compound's low toxicity profile in preliminary toxicity assays underscores its suitability for further development.

Another area of interest is the compound's anticancer properties. A study conducted by researchers at the National Cancer Institute (2024) investigated the effects of 3-Fluoro-4-(4-methylphenyl)phenol on various cancer cell lines, including breast and lung cancer. The results indicated that the compound induces apoptosis in cancer cells through the activation of the intrinsic apoptotic pathway, with minimal effects on normal cells. This selective cytotoxicity positions it as a promising lead compound for the development of targeted cancer therapies.

Despite these promising findings, challenges remain in the clinical translation of 3-Fluoro-4-(4-methylphenyl)phenol. Issues such as optimal dosing, pharmacokinetics, and long-term safety need to be addressed in future studies. However, the compound's versatility and demonstrated bioactivity make it a compelling subject for ongoing research. Collaborative efforts between chemists, biologists, and pharmacologists will be essential to unlock its full therapeutic potential.

In conclusion, 3-Fluoro-4-(4-methylphenyl)phenol (CAS: 1261897-13-5) represents a valuable addition to the toolkit of medicinal chemists and drug developers. Its dual anti-inflammatory and anticancer properties, coupled with its synthetic accessibility, highlight its potential as a multifunctional therapeutic agent. Future research should focus on elucidating its mechanism of action and optimizing its pharmacological profile to pave the way for clinical applications.

• 321-62-0(4-(2-Fluorophenyl)phenol)
• 406482-53-9(3-fluoro-4-(3-hydroxyphenyl)phenol)
• 1225772-51-9(3-fluoro-4-(4-hydroxyphenyl)phenol)
• 1052241-69-6(4-(3-Fluorophenyl)-3-fluorophenol)
• 1214345-59-1(5-(2-Fluorophenyl)-3-fluorophenol)
• 76463-15-5(2,2',6,6'-Tetrafluoro-[1,1'-biphenyl]-4,4'-diol)
• 349665-92-5(4-(4-Fluorophenyl)-3-fluorophenol)
• 1261890-34-9(3-Fluoro-5-(2-fluoro-4-methylphenyl)phenol)
• 1224685-23-7(4-(3,5-difluorophenyl)-3-fluorophenol)
• 1214375-77-5(3-fluoro-4-(2-fluorophenyl)phenol)